<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869375</url>
  </required_header>
  <id_info>
    <org_study_id>CLEARWAY-CLI</org_study_id>
    <nct_id>NCT00869375</nct_id>
  </id_info>
  <brief_title>Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia</brief_title>
  <official_title>Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atrium Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects (positive and negative) of two different
      devices available to treat people with critical limb ischemia, which involves a sudden
      decrease in blood flow to the leg that causes a potential threat to the limb and causes pain
      at rest, ulcers or gangrene.

      One device is the Clearway balloon, which delivers a drug to dissolve the clot where the
      blockage is. The other device is the Angiojet, which removes the clot in a mechanical way
      (&quot;vacuum&quot; effect). This research is being done because currently there is no single proven
      effective treatment for this condition. Even though, both these devices are commonly used in
      the clinical practice to treat critical limb ischemia, there are no studies that compare
      these devices and help us see which one may be better for these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized clinical trial in patients with peripheral vascular disease and
      acute or subacute arterial thrombosis will compare percutaneous transluminal angioplasty and
      simultaneous in situ thrombolysis using the Clearway balloon system with mechanical
      thrombectomy with the Angiojet system. Main endpoints are the time to successful
      revascularization, the frequency of distal embolization and the incidence of bleeding
      complications.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    very low enrollment due to low access to study population
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate Distal Embolization Detected by Angiographic and/or Clinical Evidence</measure>
    <time_frame>24 hours after the procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Bleeding Complications</measure>
    <time_frame>24 hours after the procedure</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>CLEARWAY GROUP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANGIOJET GROUP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular peripheral intervention</intervention_name>
    <description>Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet</description>
    <arm_group_label>CLEARWAY GROUP</arm_group_label>
    <arm_group_label>ANGIOJET GROUP</arm_group_label>
    <other_name>Clearway Balloon</other_name>
    <other_name>AngioJet Rheolytic Thrombectomy System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 18 and 85 years of age

          -  Diagnosis of acute limb ischemia (defined as an abrupt onset of lower extremity pain
             with loss of peripheral pulses and absent Doppler pulses in at least one artery and/or
             ultrasonographic evidence of decreased or absent blood flow to the affected limb) or
             Diagnosis of critical limb ischemia (defined as resting lower extremity pain with an
             ABI of &lt;0.4 and/or ultrasonographic evidence of decreased or absent blood flow to the
             affected limb).

          -  Angiographic confirmation of thrombus.

          -  Need of an intervention within 21 days of the onset of symptoms

        Exclusion Criteria:

          -  Any contraindication for thrombolytic therapy

        ABSOLUTE CONTRAINDICATIONS:

        A. Any history of intracranial hemorrhage; recent (within three months) hemorrhagic
        cerebrovascular accident (CVA) / transient ischemic attack (TIA) or significant closed head
        or facial injury.

        B. Known intracranial neoplasm or arteriovenous malformation. C. Suspected aortic
        dissection. D. Active bleeding diathesis or hemostatic defects: (Excluding menses); active
        internal

        RELATIVE CONTRAINDICATIONS:

        Fibrinolytic therapy may be used with the presence of these conditions upon clinical
        assessment or treatment dependent upon bleeding risks:

        A. History of chronic, severe, and poorly controlled blood pressure or Severe uncontrolled
        hypertension on presentation (SBP &gt;180, DBP &gt;110).

        B. History of prior ischemic stroke (greater than 3 months) dementia, or known intracranial
        pathology not covered in absolute contraindications.

        C. Traumatic or prolonged CPR (&gt; 10 minutes), major surgery (&lt; 3 weeks), or recent trauma,
        including head trauma (2-4 weeks).

        D. Recent (within 2 to 4 weeks) internal bleeding. E. Noncompressible vascular punctures.
        F. Pregnancy or recent obstetrical delivery. G. Active peptic ulcer disease. H.
        Anticoagulant use (INR &gt; 2-3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Emilio Exaire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <results_first_submitted>April 4, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2014</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute or critical limb ischemia with angiographic thrombus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CLEARWAY GROUP</title>
          <description>3 patients were randomized in this group.</description>
        </group>
        <group group_id="P2">
          <title>ANGIOJET GROUP</title>
          <description>3 patients were randomized in this group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CLEARWAY GROUP</title>
          <description>3 patients were randomized in this group.</description>
        </group>
        <group group_id="B2">
          <title>ANGIOJET GROUP</title>
          <description>3 patients were randomized in this group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="42" upper_limit="49"/>
                    <measurement group_id="B2" value="63" lower_limit="57" upper_limit="74"/>
                    <measurement group_id="B3" value="54" lower_limit="42" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smokers</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immediate Distal Embolization Detected by Angiographic and/or Clinical Evidence</title>
        <time_frame>24 hours after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CLEARWAY GROUP</title>
            <description>No patients had distal embolization</description>
          </group>
          <group group_id="O2">
            <title>ANGIOJET GROUP</title>
            <description>No patients had distal embolization</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Distal Embolization Detected by Angiographic and/or Clinical Evidence</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Bleeding Complications</title>
        <time_frame>24 hours after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CLEARWAY GROUP</title>
            <description>4 patients were randomized in this group. One patient was excluded since intervention was not required.</description>
          </group>
          <group group_id="O2">
            <title>ANGIOJET GROUP</title>
            <description>3 patients were randomized in this group</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Bleeding Complications</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CLEARWAY GROUP</title>
          <description>4 patients were randomized in this group. One patient was excluded since intervention was not required.</description>
        </group>
        <group group_id="E2">
          <title>ANGIOJET GROUP</title>
          <description>3 patients were randomized in this group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency surgery</sub_title>
                <description>One patient in the clearway group required emergency embolectomy due to failure to revascularize. This was not deemed to be secondary to a failure of strategy or failure of device but rather to the severity and extension of the thrombbus.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The main limitation of this trial was slow enrollment. This led to early termination leading to small numbers of subjects analyzed. This makes the results uninterpretable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>J. Emilio Exaire MD</name_or_title>
      <organization>OUHSC</organization>
      <phone>405 271 4742 ext 44744</phone>
      <email>jose-exaire@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

